Insights into the Use of Peripherally Acting µ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice.
Por:
Fernandez-Montes, A, de Velasco, G, Aguin, S, Farriols, C, Guirado-Risueno, M, Jerviz-Guia, V, Baeza-Nadal, M, Chicas-Sett, R, Firvida, J, Garcia-Navalon, F, Martin, P, Perezagua-Marin, C, Rodriguez, D, Santamaria, J, Sauri, T and Cobo, M
Publicada:
26 feb 2021
Ahead of Print:
26 feb 2021
Resumen:
Management of chronic pain is crucial to improve the quality of life of cancer and palliative care patients. Opioid-based treatments used to control pain can be prolonged over time. Unfortunately, constipation is one of the most disturbing adverse effects of long-term use of opioids. Opioid-induced constipation (OIC) occurs when opioids bind to the specific receptors present in the gastrointestinal (GI) tract, and can affect any patients receiving chronic opioid therapy, including cancer patients. The limited efficacy of laxatives to treat OIC symptoms prompted the search for new therapeutic strategies. Peripherally acting µ-opioid receptor antagonists (PAMORAs) have recently emerged as new effective drugs for OIC management due to their specific binding to enteric µ-receptors. Little information is available on the use of PAMORAs in real-life practice for OIC treatment in cancer patients. In this paper, a panel of experts specializing in cancer and palliative care pools their clinical experience with PAMORAs in cancer patients presenting OIC and highlights the importance of timing and choice of therapy in achieving prompt OIC management and benefitting patients.
Filiaciones:
Fernandez-Montes, A:
Complexo Hosp Ourense, Med Oncol, Ramon Puga 54, Orense 32003, Spain
de Velasco, G:
Hosp Univ 12 Octubre, Medicat Oncol, Madrid, Spain
Aguin, S:
Complejo Hosp Univ Santiago de Composteta, Med Oncol, La Coruna, Spain
Farriols, C:
Hosp del Mar, Palliat Care Unit, Barcelona, Spain
:
Hosp Gen Univ Elche, Med Oncol, Alicante, Spain
Jerviz-Guia, V:
Hosp Univ Clin San Cecilio, Oncol Radiotherapy Unit, Granada, Spain
Baeza-Nadal, M:
Complejo Hosp Univ, Palliat Unit Care, Toledo, Spain
Chicas-Sett, R:
Hosp Univ Doctor Negrin, Radiat Oncol, Las Palmas Gran Canaria, Spain
Firvida, J:
Hosp Cosaga, Med Oncol, Orense, Spain
Garcia-Navalon, F:
Hosp Univ Son Llatzer, Med Oncol, Palma De Mallorca, Spain
:
Hosp Marina Baixa Villajoyosa, Med Oncol, Alicante, Spain
Perezagua-Marin, C:
Hosp Henares, Med Oncol, Madrid, Spain
Rodriguez, D:
Hosp Univ St Joan de Reus, Palliat Care Unit, Tarragona, Spain
Santamaria, J:
Hosp Univ Son Espases, Palliat Care Unit, Palma De Mallorca, Islas Baleares, Spain
Sauri, T:
Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
IDIBAPS, Tianslat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
Cobo, M:
Hosp Univ Reg & Virgen de la Victoria, IBIMA, Med Oncol, Malaga, Spain
|